The Booth Gardner Parkinson’s Care Center is conducting a randomized, double-blind, placebo-controlled, Phase 3 study of an investigational drug, donanemab, in patients with early symptomatic Alzheimer’s disease (AD).
Who may be eligible to participate?
Male or female subjects, 60 to 85 years of age, with gradual and progressive change in memory function reported by the participant or informant for ≥6 months. Must have study partner to participate. Other inclusion/exclusion criteria apply.
What does participation involve?
Participants who meet eligibility criteria will be randomized in a 1:1 ratio to either investigational drug -donanemab or placebo. The maximum total duration of study participation for each participant, including screening, treatment, and the post-treatment follow-up periods, is up to 127 weeks.
Pinky Agarwal, M.D., FAAN